Chapter title |
Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia
|
---|---|
Chapter number | 1 |
Book title |
Chronic Myeloid Leukemia
|
Published in |
Methods in molecular biology, January 2016
|
DOI | 10.1007/978-1-4939-4011-0_1 |
Pubmed ID | |
Book ISBNs |
978-1-4939-4009-7, 978-1-4939-4011-0
|
Authors |
Ya-Zhen Qin, Xiao-Jun Huang, Qin, Ya-Zhen, Huang, Xiao-Jun |
Abstract |
All chronic myeloid leukemia (CML) patients have the BCR-ABL fusion gene. The constitutively activated BCR-ABL tyrosine kinase is a critical pathogenetic event in CML. Tyrosine kinase inhibitors (TKIs), such as imatinib, are synthesized small molecules that primarily target BCR-ABL tyrosine kinases and have become a first-line treatment for CML. Detection of BCR-ABL transcript level by real-time quantitative polymerase chain reaction (RQ-PCR) is a clinical routine for evaluating TKI treatment efficacy and predicting long-term response. Furthermore, because they are a main TKI resistance mechanism, the BCR-ABL tyrosine kinase domain (TKD) point mutations that are detected by Sanger sequencing can help clinicians make decisions on subsequent treatment selections. Here, we present protocols for the two abovementioned molecular methods for CML analysis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 10 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 30% |
Student > Master | 2 | 20% |
Other | 1 | 10% |
Unknown | 4 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 3 | 30% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
Medicine and Dentistry | 1 | 10% |
Engineering | 1 | 10% |
Unknown | 4 | 40% |